Study details
Enrolling now
Tocilizumab for Acute Chest Syndrome
University of Chicago
NCT IDNCT05640271ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
200
Study length
about 3.8 years
Ages
12+
Locations
1 site in IL
About this study
This trial is testing if a low dose of tocilizumab, a medication that blocks interleukin-6 (IL-6), can help treat acute chest syndrome in people with sickle cell disease. The goal is to see how this treatment affects oxygen levels, clinical outcomes, and lab results for patients hospitalized with acute chest syndrome.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Tocilizumab
PhasePhase 2
DrugTocilizumab
Routeinfusion
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
tocilizumab (Monoclonal antibody; blocks IL-6 receptor to reduce inflammation)
Drug routes
infusion
Endpoints
Secondary: Length of stay, Mortality rate, Readmission rate